Inflammatory cardiomyopathy is defined as inflammation of the heart muscle associated with impaired function of the myocardium. In our region, its etiology is most often viral. Viral infection is a possible trigger of immune and autoimmune mechanisms which contributed to the damage of myocardial function. Myocarditis is considered the most common cause of dilated cardiomyopathy. Typical manifestation of this disease is heart failure, chest pain, or arrhythmias. The most important noninvasive diagnostic method is magnetic resonance imaging, but the gold standard of diagnostics is invasive examination, endomyocardial biopsy. In a significant proportion of cases with impaired left ventricular systolic function, recovery occurs spontaneously in several weeks and therefore it is appropriate to postpone critical therapeutic decisions about 3-6 months after start of the treatment. Therapy is based on standard heart failure treatment; immunosuppressive or antimicrobial treatment may be considered in some cases depending on the results of endomyocardial biopsy. If severe dysfunction of the left ventricle persists, device therapy may be needed.

Department of Cardiovascular Diseases St Anne's University Hospital International Clinical Research Center Pekarska 53 65691 Brno Czech Republic; International Clinical Research Center and Masaryk University Brno Czech Republic

International Clinical Research Center and Masaryk University Brno Czech Republic

International Clinical Research Center and Masaryk University Brno Czech Republic; Centre for Cardiovascular Surgery and Transplantation Brno Czech Republic

Zobrazit více v PubMed

Richardson P., McKenna R. W., Bristow M., et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation. 1996;93(5):841–842. doi: 10.1161/01.cir.93.5.841. PubMed DOI

Caforio A. L. P., Pankuweit S., Arbustini E., et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart Journal. 2013;34(33):2636–2648. doi: 10.1093/eurheartj/eht210. PubMed DOI

Hufnagel G., Pankuweit S., Richter A., Schönian U., Maisch B. The European Study of Epidemiology and Treatment of Cardiac Inflammatory Diseases (ESETCID): first epidemiological results. Herz. 2000;25(3):279–285. doi: 10.1007/s000590050021. PubMed DOI

Breinholt J. P., Moulik M., Dreyer W. J., et al. Viral epidemiologic shift in inflammatory heart disease: the increasing involvement of parvovirus B19 in the myocardium of pediatric cardiac transplant patients. Journal of Heart and Lung Transplantation. 2010;29(7):739–746. doi: 10.1016/j.healun.2010.03.003. PubMed DOI PMC

Maisch B., Pankuweit S. Current treatment options in (peri)myocarditis and inflammatory cardiomyopathy. Herz. 2012;37(6):644–656. doi: 10.1007/s00059-012-3679-9. PubMed DOI

Malik L. H., Singh G. D., Amsterdam E. A. The epidemiology, clinical manifestations, and management of chagas heart disease. Clinical Cardiology. 2015;38(9):565–569. doi: 10.1002/clc.22421. PubMed DOI PMC

Palecek T., Kuchynka P., Hulinska D., et al. Presence of Borrelia burgdorferi in endomyocardial biopsies in patients with new-onset unexplained dilated cardiomyopathy. Medical Microbiology and Immunology. 2010;199(2):139–143. doi: 10.1007/s00430-009-0141-6. PubMed DOI

Kubánek M., Šramko M., Berenová D., et al. Detection of Borrelia burgdorferi sensu lato in endomyocardial biopsy specimens in individuals with recent-onset dilated cardiomyopathy. European Journal of Heart Failure. 2012;14(6):588–596. doi: 10.1093/eurjhf/hfs027. PubMed DOI

Cooper L. T., Jr. Myocarditis. The New England Journal of Medicine. 2009;360(15):1526–1538. doi: 10.1056/nejmra0800028. PubMed DOI PMC

Kindermann I., Barth C., Mahfoud F., et al. Update on myocarditis. Journal of the American College of Cardiology. 2012;59(9):779–792. doi: 10.1016/j.jacc.2011.09.074. PubMed DOI

Dennert R., Crijns H. J., Heymans S. Acute viral myocarditis. European Heart Journal. 2008;29(17):2073–2082. doi: 10.1093/eurheartj/ehn296. PubMed DOI PMC

Noutsias M., Pauschinger M., Poller W.-C., Schultheiss H.-P., Kühl U. Current insights into the pathogenesis, diagnosis and therapy of inflammatory cardiomyopathy. Heart Failure Monitor. 2003;3(4):127–135. PubMed

Caforio A. L. P., Bottaro S., Iliceto S. Dilated cardiomyopathy (DCM) and myocarditis: classification, clinical and autoimmune features. Applied Cardiopulmonary Pathophysiology. 2012;16(1):82–95.

Wehlou C., Delanghe J. R. Detection of antibodies in cardiac autoimmunity. Clinica Chimica Acta. 2009;408(1-2):114–122. doi: 10.1016/j.cca.2009.08.002. PubMed DOI

Caforio A. L. P., Mahon N. J., Tona F., McKenna W. J. Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance. European Journal of Heart Failure. 2002;4(4):411–417. doi: 10.1016/s1388-9842(02)00010-7. PubMed DOI

Rose N. R. Myocarditis: infection versus autoimmunity. Journal of Clinical Immunology. 2009;29(6):730–737. doi: 10.1007/s10875-009-9339-z. PubMed DOI

Schultheiss H.-P., Khl U., Cooper L. T. The management of myocarditis. European Heart Journal. 2011;32(21):2616–2625. doi: 10.1093/eurheartj/ehr165. PubMed DOI

D'Ambrosio A., Patti G., Manzoli A., et al. The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: a review. Heart. 2001;85(5):499–504. doi: 10.1136/heart.85.5.499. PubMed DOI PMC

Caforio A. L. P., Marcolongo R., Basso C., Iliceto S. Clinical presentation and diagnosis of myocarditis. Heart. 2015;101(16):1332–1344. doi: 10.1136/heartjnl-2014-306363. PubMed DOI

Mason J. W., O'Connell J. B., Herskowitz A., et al. A clinical trial of immunosuppressive therapy for myocarditis. The New England Journal of Medicine. 1995;333(5):269–275. doi: 10.1056/nejm199508033330501. PubMed DOI

Kühl U., Pauschinger M., Noutsias M., et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with ‘idiopathic’ left ventricular dysfunction. Circulation. 2005;111(7):887–893. doi: 10.1161/01.cir.0000155616.07901.35. PubMed DOI

Krejčí J., Poloczková H., Hude P., et al. Impact of inflammatory infiltration and viral genome presence in myocardium on the changes of echocardiographic parameters. Cor et Vasa. 2013;55(4):e333–e340. doi: 10.1016/j.crvasa.2013.02.003. DOI

Kühl U. Antiviral treatment of myocarditis and acute dilated cardiomyopathy. Heart Failure Clinics. 2005;1(3):467–474. doi: 10.1016/j.hfc.2005.06.014. PubMed DOI

Kuethe F., Lindner J., Matschke K., et al. Prevalence of parvovirus B19 and human bocavirus DNA in the heart of patients with no evidence of dilated cardiomyopathy or myocarditis. Clinical Infectious Diseases. 2009;49(11):1660–1666. doi: 10.1086/648074. PubMed DOI

Escher F., Modrow S., Sabi T., et al. Parvovirus B19 profiles in patients presenting with acute myocarditis and chronic dilated cardiomyopathy. Medical Science Monitor. 2008;14(12):CR589–CR597. PubMed

Koepsell S. A., Anderson D. R., Radio S. J. Parvovirus B19 is a bystander in adult myocarditis. Cardiovascular Pathology. 2012;21(6):476–481. doi: 10.1016/j.carpath.2012.02.002. PubMed DOI

Stewart G. C., Lopez-Molina J., Gottumukkala R. V. S. R. K., et al. Myocardial Parvovirus B19 persistence: lack of association with clinicopathologic Phenotype in adults with heart failure. Circulation: Heart Failure. 2011;4(1):71–78. doi: 10.1161/circheartfailure.110.958249. PubMed DOI PMC

Caforio A. L. P., Calabrese F., Angelini A., et al. A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. European Heart Journal. 2007;28(11):1326–1333. doi: 10.1093/eurheartj/ehm076. PubMed DOI

Kühl U., Lassner D., von Schlippenbach J., Poller W., Schultheiss H.-P. Interferon-beta improves survival in enterovirus-associated cardiomyopathy. Journal of the American College of Cardiology. 2012;60(14):1295–1296. doi: 10.1016/j.jacc.2012.06.026. PubMed DOI

Kindermann I., Kindermann M., Kandolf R., et al. Predictors of outcome in patients with suspected myocarditis. Circulation. 2008;118(6):639–648. doi: 10.1161/circulationaha.108.769489. PubMed DOI

Bock C.-T., Klingel K., Kandolf R. Human parvovirus B19-associated myocarditis. New England Journal of Medicine. 2010;362(13):1248–1249. doi: 10.1056/NEJMc0911362. PubMed DOI

Pankuweit S., Klingel K. Viral myocarditis: from experimental models to molecular diagnosis in patients. Heart Failure Reviews. 2013;18(6):683–702. doi: 10.1007/s10741-012-9357-4. PubMed DOI

Bock C. T., Düchting A., Utta F. Molecular phenotypes of human parvovirus B19 in patients with myokarditis. World Journal of Cardiology. 2014;6:183–195. PubMed PMC

Lassner D., Rohde M., Siegismund C. S., et al. Myocarditis—personalized medicine by expanded endomyocardial biopsy diagnostics. World Journal of Cardiovascular Diseases. 2014;4(6):325–340. doi: 10.4236/wjcd.2014.46042. DOI

Fairweather D., Cooper L. T., Jr., Blauwet L. A. Sex and gender differences in myocarditis and dilated cardiomyopathy. Current Problems in Cardiology. 2013;38(1):7–46. doi: 10.1016/j.cpcardiol.2012.07.003. PubMed DOI PMC

McCarthy R. E., III, Boehmer J. P., Hruban R. H., et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. The New England Journal of Medicine. 2000;342(10):690–695. doi: 10.1056/nejm200003093421003. PubMed DOI

Krejci J., Hude P., Poloczkova H., et al. Correlations of the changes in bioptic findings with echocardiographic, clinical and laboratory parameters in patients with inflammatory cardiomyopathy. Heart and Vessels. 2016;31:416–426. doi: 10.1007/s00380-014-0618-0. PubMed DOI

Tschöpe C., Bock C.-T., Kasner M., et al. High prevalence of cardiac parvovirus B19 infection in patients with isolated left ventricular diastolic dysfunction. Circulation. 2005;111(7):879–886. doi: 10.1161/01.CIR.0000155615.68924.B3. PubMed DOI

Baccouche H., Mahrholdt H., Meinhardt G., et al. Diagnostic synergy of non-invasive cardiovascular magnetic resonance and invasive endomyocardial biopsy in troponin-positive patients without coronary artery disease. European Heart Journal. 2009;30(23):2869–2879. doi: 10.1093/eurheartj/ehp328. PubMed DOI

Krejci J., Hude P., Spinarova L., et al. The variable clinical course of peripartum cardiomyopathy. Biomedical Papers. 2014;158(1):92–97. doi: 10.5507/bp.2012.080. PubMed DOI

Bültmann B. D., Klingel K., Näbauer M., Wallwiener D., Kandolf R. High prevalence of viral genomes and inflammation in peripartum cardiomyopathy. American Journal of Obstetrics and Gynecology. 2005;193(2):363–365. doi: 10.1016/j.ajog.2005.01.022. PubMed DOI

Midei M. G., DeMent S. H., Feldman A. M., Hutchins G. M., Baughman K. L. Peripartum myocarditis and cardiomyopathy. Circulation. 1990;81(3):922–928. doi: 10.1161/01.CIR.81.3.922. PubMed DOI

Sliwa K., Hilfiker-Kleiner D., Petrie M. C., et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. European Journal of Heart Failure. 2010;12(8):767–778. doi: 10.1093/eurjhf/hfq120. PubMed DOI

Blauwet L. A., Cooper L. T. Diagnosis and management of peripartum cardiomyopathy. Heart. 2011;97(23):1970–1981. doi: 10.1136/heartjnl-2011-300349. PubMed DOI

Gentry M. B., Dias J. K., Luis A., Patel R., Thornton J., Reed G. L. African-American women have a higher risk for developing Peripartum cardiomyopathy. Journal of the American College of Cardiology. 2010;55(7):654–659. doi: 10.1016/j.jacc.2009.09.043. PubMed DOI PMC

Cooper L. T., Mather P. J., Alexis J. D., et al. Myocardial recovery in peripartum cardiomyopathy: prospective comparison with recent onset cardiomyopathy in men and nonperipartum women. Journal of Cardiac Failure. 2012;18(1):28–33. doi: 10.1016/j.cardfail.2011.09.009. PubMed DOI PMC

Amos A. M., Jaber W. A., Russell S. D. Improved outcomes in peripartum cardiomyopathy with contemporary. American Heart Journal. 2006;152(3):509–513. doi: 10.1016/j.ahj.2006.02.008. PubMed DOI

Safirstein J. G., Ro A. S., Grandhi S., Wang L., Fett J. D., Staniloae C. Predictors of left ventricular recovery in a cohort of peripartum cardiomyopathy patients recruited via the internet. International Journal of Cardiology. 2012;154(1):27–31. doi: 10.1016/j.ijcard.2010.08.065. PubMed DOI

Krejci J., Poloczkova H., Nemec P. Current therapeutic concepts in peripartum cardiomyopathy. Current Pharmaceutical Design. 2015;21(4):507–514. doi: 10.2174/138161282104141204144035. PubMed DOI

Friedrich M. G., Sechtem U., Schulz-Menger J., et al. Cardiovascular magnetic resonance in myocarditis: a JACC White Paper. Journal of the American College of Cardiology. 2009;53(17):1475–1487. doi: 10.1016/j.jacc.2009.02.007. PubMed DOI PMC

Olimulder M. A. G. M., van Es J., Galjee M. A. The importance of cardiac MRI as a diagnostic tool in viral myocarditis-induced cardiomyopathy. Netherlands Heart Journal. 2009;17(12):481–486. doi: 10.1007/s12471-010-0007-y. PubMed DOI PMC

Bruder O., Wagner A., Lombardi M., et al. European Cardiovascular Magnetic Resonance (EuroCMR) registry—multi national results from 57 centers in 15 countries. Journal of Cardiovascular Magnetic Resonance. 2013;15, article 9 doi: 10.1186/1532-429x-15-9. PubMed DOI PMC

Lurz P., Eitel I., Adam J., et al. Diagnostic performance of CMR imaging compared with EMB in patients with suspected myocarditis. JACC Cardiovascular Imaging. 2012;5(5):513–524. doi: 10.1016/j.jcmg.2011.11.022. PubMed DOI

Kuchynka P., Palecek T., Nemecek E., Fikrle M., Linhart A. New therapeutic aspects on inflammatory cardiomyopathy. Current Pharmaceutical Design. 2015;21(4):459–465. PubMed

Grün S., Schumm J., Greulich S., et al. Long-term follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery. Journal of the American College of Cardiology. 2012;59(18):1604–1615. doi: 10.1016/j.jacc.2012.01.007. PubMed DOI

Francone M., Chimenti C., Galea N., et al. CMR sensitivity varies with clinical presentation and extent of cell necrosis in biopsy-proven acute myocarditis. JACC Cardiovascular Imaging. 2014;7(3):254–263. doi: 10.1016/j.jcmg.2013.10.011. PubMed DOI

Lauer B., Niederau C., Kühl U., et al. Cardiac troponin T in patients with clinically suspected myocarditis. Journal of the American College of Cardiology. 1997;30(5):1354–1359. doi: 10.1016/S0735-1097(97)00317-3. PubMed DOI

Ukena C., Kindermann M., Mahfoud F., et al. Diagnostic and prognostic validity of different biomarkers in patients with suspected myocarditis. Clinical Research in Cardiology. 2014;103(9):743–751. doi: 10.1007/s00392-014-0709-z. PubMed DOI

Frustaci A., Chimenti C., Calabrese F., Pieroni M., Thiene G., Maseri A. Immunosuppressive therapy for active lymphocytic myocarditis. Virological and immunologic profile of responders versus nonresponders. Circulation. 2003;107(6):857–866. doi: 10.1161/01.cir.0000048147.15962.31. PubMed DOI

Mahfoud F., Grtner B., Kindermann M., et al. Virus serology in patients with suspected myocarditis: utility or futility? European Heart Journal. 2011;32(7):897–903. doi: 10.1093/eurheartj/ehq493. PubMed DOI

Heidecker B., Kittleson M. M., Kasper E. K., et al. Transcriptomic biomarkers for the accurate diagnosis of myocarditis. Circulation. 2011;123(11):1174–1184. doi: 10.1161/circulationaha.110.002857. PubMed DOI PMC

Cooper L. T., Jr., Onuma O. K., Sagar S., et al. Genomic and proteomic analysis of myocarditis and dilated cardiomyopathy. Heart Failure Clinics. 2010;6(1):75–85. doi: 10.1016/j.hfc.2009.08.012. PubMed DOI

Corsten M. F., Papageorgiou A., Verhesen W., et al. MicroRNA profiling identifies MicroRNA-155 as an adverse mediator of cardiac injury and dysfunction during Acute Viral MyoCarditis. Circulation Research. 2012;111(4):415–425. doi: 10.1161/circresaha.112.267443. PubMed DOI

Bao J.-L., Lin L. MiR-155 and miR-148a reduce cardiac injury by inhibiting NF-κB pathway during acute viral myocarditis. European Review for Medical and Pharmacological Sciences. 2014;18(16):2349–2356. PubMed

Kühl U., Rohde M., Lassner D., Gross U. M., Escher F., Schultheiss H.-P. miRNA as activity markers in Parvo B19 associated heart disease. Herz. 2012;37(6):637–643. doi: 10.1007/s00059-012-3656-3. PubMed DOI

Kühl U., Lassner D., Dorner A., et al. A distinct subgroup of cardiomyopathy patients characterized by transcriptionally active cardiotropic erythrovirus and altered cardiac gene expression. Basic Research in Cardiology. 2013;108, article 372 doi: 10.1007/s00395-013-0372-y. PubMed DOI

Escher F., Lassner D., Kühl U., et al. Analysis of endomyocardial biopsies in suspected myocarditis—diagnostic value of left versus right ventricularbiopsy. International Journal of Cardiology. 2014;177(1):76–78. doi: 10.1016/j.ijcard.2014.09.071. PubMed DOI

Yilmaz A., Kindermann I., Kindermann M., et al. Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance. Circulation. 2010;122(9):900–909. doi: 10.1161/circulationaha.109.924167. PubMed DOI

Chimenti C., Frustaci A. Contribution and risks of left ventricular endomyocardial biopsy in patients with cardiomyopathies: a retrospective study over a 28-year period. Circulation. 2013;128(14):1531–1541. doi: 10.1161/circulationaha.13.001414. PubMed DOI

Aretz H. T., Billingham M. E., Edwards W. D., et al. Myocarditis. A histopathologic definition and classification. The American Journal of Cardiovascular Pathology. 1987;1(1):3–14. PubMed

Baughman K. L. Diagnosis of myocarditis: death of Dallas criteria. Circulation. 2006;113(4):593–595. doi: 10.1161/circulationaha.105.589663. PubMed DOI

Kühl U., Noutsias M., Seeberg B., Schultheiss H.-P. Immunohistological evidence for a chronic intramyocardial inflammatory process in dilated cardiomyopathy. Heart. 1996;75(3):295–300. doi: 10.1136/hrt.75.3.295. PubMed DOI PMC

Cooper L. T., Baughman K. L., Feldman A. M., et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation. 2007;116(19):2216–2233. doi: 10.1161/circulationaha.107.186093. PubMed DOI

From A. M., Maleszewski J. J., Rihal C. S. Current status of endomyocardial biopsy. Mayo Clinic Proceedings. 2011;86(11):1095–1102. doi: 10.4065/mcp.2011.0296. PubMed DOI PMC

Thiene G., Bruneval P., Veinot J., Leone O. Diagnostic use of the endomyocardial biopsy: a consensus statement. Virchows Archiv. 2013;463(1):1–5. doi: 10.1007/s00428-013-1430-4. PubMed DOI

Maisch B., Portig I., Ristic A., Hufnagel G., Pankuweit S. Definition of inflammatory cardiomyopathy (myocarditis): on the way to consensus: a status report. Herz. 2000;25(3):200–209. doi: 10.1007/s000590050007. PubMed DOI

Frustaci A., Russo M. A., Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. European Heart Journal. 2009;30(16):1995–2002. doi: 10.1093/eurheartj/ehp249. PubMed DOI

Escher F., Kühl U., Lassner D., et al. Presence of perforin in endomyocardial biopsies of patients with inflammatory cardiomyopathy predicts poor outcome. European Journal of Heart Failure. 2014;16(10):1066–1072. doi: 10.1002/ejhf.148. PubMed DOI

Wojnicz R., Nowalany-Kozielska E., Wojciechowska C., et al. Randomized, placebo- controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy. Two-year follow-up results. Circulation. 2001;104(1):39–45. doi: 10.1161/01.cir.104.1.39. PubMed DOI

Chow L. H., Radio S. J., Sears T. D., Mcmanus B. M. Insensitivity of right ventricular endomyocardial biopsy in the diagnosis of myocarditis. Journal of the American College of Cardiology. 1989;14(4):915–920. doi: 10.1016/0735-1097(89)90465-8. PubMed DOI

Hauck A. J., Kearney D. L., Edwards W. D. Evaluation of postmortem endomyocardial biopsy specimens from 38 patients with lymphocytic myocarditis: implications for role of sampling error. Mayo Clinic Proceedings. 1989;64(10):1235–1245. doi: 10.1016/s0025-6196(12)61286-5. PubMed DOI

McMurray J. J. V., Adamopoulos S., Anker S. D., et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2012;33(14):1787–1847. doi: 10.1093/eurheartj/ehs104. PubMed DOI

Yancy C. W., Jessup M., Bozkurt B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):e240–e327. doi: 10.1161/cir.0b013e31829e8776. PubMed DOI

Bahk T. J., Daniels M. D., Leon J. S., Wang K., Engman D. M. Comparison of angiotensin converting enzyme inhibition and angiotensin II receptor blockade for the prevention of experimental autoimmune myocarditis. International Journal of Cardiology. 2008;125(1):85–93. doi: 10.1016/j.ijcard.2007.04.062. PubMed DOI PMC

Saegusa S., Fei Y., Takahashi T., et al. Oral administration of candesartan improves the survival of mice with viral myocarditis through modification of cardiac adiponectin expression. Cardiovascular Drugs and Therapy. 2007;21(3):155–160. doi: 10.1007/s10557-007-6024-4. PubMed DOI

Yuan Z., Shioji K., Kihara Y., Takenaka H., Onozawa Y., Kishimoto C. Cardioprotective effects of carvedilol on acute autoimmune myocarditis: anti-inflammatory effects associated with antioxidant property. American Journal of Physiology—Heart and Circulatory Physiology. 2004;286(1):H83–H90. PubMed

Pauschinger M., Rutschow S., Chandrasekharan K., et al. Carvedilol improves left ventricular function in murine coxsackievirus-induced acute myocarditis: association with reduced myocardial interleukin-1β and MMP-8 expression and a modulated immune response. European Journal of Heart Failure. 2005;7(4):444–452. doi: 10.1016/j.ejheart.2004.07.002. PubMed DOI

Xiao J., Shimada M., Liu W., Hu D., Matsumori A. Anti-inflammatory effects of eplerenone on viral myocarditis. European Journal of Heart Failure. 2009;11(4):349–353. doi: 10.1093/eurjhf/hfp023. PubMed DOI

Cooper L. T., Jr., Berry G. J., Shabetai R. Idiopathic giant-cell myocarditis-natural history and treatment. The New England Journal of Medicine. 1997;336(26):1860–1866. doi: 10.1056/nejm199706263362603. PubMed DOI

Cooper L. T., Jr., Hare J. M., Tazelaar H. D., et al. Usefulness of immunosuppression for giant cell myocarditis. American Journal of Cardiology. 2008;102(11):1535–1539. doi: 10.1016/j.amjcard.2008.07.041. PubMed DOI PMC

Kandolin R., Lehtonen J., Salmenkivi K., Räisänen-Sokolowski A., Lommi J., Kupari M. Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression. Circulation: Heart Failure. 2013;6(1):15–22. doi: 10.1161/CIRCHEARTFAILURE.112.969261. PubMed DOI

Kawano S., Kato J., Kawano N., et al. Clinical features and outcomes of eosinophilic myocarditis patients treated with prednisolone at a single institution over a 27-year period. Internal Medicine. 2011;50(9):975–981. doi: 10.2169/internalmedicine.50.4079. PubMed DOI

Yanagisawa T., Inomata T., Watanabe I., et al. Clinical significance of corticosteroid therapy for eosinophilic myocarditis. International Heart Journal. 2011;52(2):110–113. doi: 10.1536/ihj.52.110. PubMed DOI

Blauwet L. A., Cooper L. T. Idiopathic giant cell myocarditis and cardiac sarcoidosis. Heart Failure Reviews. 2013;18(6):733–746. doi: 10.1007/s10741-012-9358-3. PubMed DOI

Frustaci A., Chimenti C. Immunosuppressive therapy in myocarditis. Circulation Journal. 2014;79(1):4–7. doi: 10.1253/circj.CJ-14-1192. PubMed DOI

Stanton C., Mookadam F., Cha S., et al. Greater symptom duration predicts response to immunomodulatory therapy in dilated cardiomyopathy. International Journal of Cardiology. 2008;128(1):38–41. doi: 10.1016/j.ijcard.2007.05.016. PubMed DOI

Lu C., Qui F., Yan Y., Liu T., Li J., Chen H. Immunosuppressive treatment for myocarditis: a meta-analysis of randomized controlled trials. Journal of Cardiovascular Medicine. 2014 doi: 10.2459/JCM.0000000000000134. PubMed DOI

Mason J. W., O'Connell J. B., Herskowitz A., et al. A clinical trial of immunosuppressive therapy for myocarditis. The New England Journal of Medicine. 1995;333(5):269–275. doi: 10.1056/nejm199508033330501. PubMed DOI

Palecek T., Krejci J., Pecen L., et al. Czech Inflammatory Cardiomyopathy Immunosuppression Trial (CZECH-ICIT): randomized, multicentric study comparing the effect of two regimens of combined immunosuppressive therapy in the treatment of inflammatory cardiomyopathy: the aims and design of the trial. Cor et Vasa. 2013;55(6):e475–e478. doi: 10.1016/j.crvasa.2013.08.001. DOI

Gullestad L., Aass H., Fjeld J. G., et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation. 2001;103(2):220–225. doi: 10.1161/01.cir.103.2.220. PubMed DOI

Dennert R., Velthuis S., Schalla S., et al. Intravenous immunoglobulin therapy for patients with idiopathic cardiomyopathy and endomyocardial biopsy-proven high PVB19 viral load. Antiviral Therapy. 2010;15(2):193–201. doi: 10.3851/imp1516. PubMed DOI

McNamara D. M., Holubkov R., Starling R. C., et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation. 2001;103(18):2254–2259. doi: 10.1161/01.CIR.103.18.2254. PubMed DOI

Staudt A., Hummel A., Ruppert J., et al. Immunoadsorption in dilated cardiomyopathy: 6-month results from a randomized study. American Heart Journal. 2006;152(4):712.e1–712.e6. doi: 10.1016/j.ahj.2006.06.027. PubMed DOI

Felix S. B., Staudt A., Dörffer W. V. Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three-month results from a randomized study. Journal of the American College of Cardiology. 2000;35(6):1590–1598. doi: 10.1016/s0735-1097(00)00568-4. PubMed DOI

Kühl U., Pauschinger M., Schwimmbeck P. L., et al. Interferon-β treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation. 2003;107(22):2793–2798. doi: 10.1161/01.CIR.0000072766.67150.51. PubMed DOI

Zimmermann O., Rodewald C., Radermacher M., et al. Interferon β-1b therapy in chronic viral dilated cardiomyopathy—is there a role for specific therapy? Journal of Cardiac Failure. 2010;16(4):348–356. doi: 10.1016/j.cardfail.2009.12.016. PubMed DOI

Elevated Sera sST2 Is Associated With Heart Failure in Men ≤50 Years Old With Myocarditis